Comprehensive analysis of the efficacy and role of lenvatinib/lenvatinib (Lenvima)

Lenvatinib/Lenvatinib (Lenvatinib) is a multi-target tyrosine kinase inhibitor (TKI) developed by Japan's Eisai Pharmaceuticals (Eisai). It blocks tumor angiogenesis and inhibits the proliferation and metastasis of tumor cells by inhibiting a variety of signaling pathways related to tumor growth, especially vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), platelet-derived growth factor receptors (PDGFRα), RET and KIT. Different from traditional chemotherapy, lenvatinib's advantage lies in "precise targeting". It can not only directly interfere with tumor cell signaling pathways, but also improve the tumor microenvironment, delay disease progression, and show stable and significant efficacy in a variety of solid tumors.

In the treatment of renal cell carcinoma (RCC), lenvatinib is usually used in advanced or metastatic cases. Studies have shown that when lenvatinib is combined with immune drugs (such as pembrolizumab), it can improve the overall response rate and survival of patients. This combination strategy has been recommended in multiple cancer guidelines around the world and has become one of the first-line options for advanced renal cancer. The mechanism lies in the complementary effects of the two: lenvatinib inhibits tumor angiogenesis, creates a more favorable tumor microenvironment for immune drugs, and makes it easier for immune cells to recognize and kill cancer cells. This synergistic effect makes lenvatinib show better clinical prospects than single agent in the treatment of renal cancer.

In terms of hepatocellular carcinoma (HCC), lenvatinib is widely used in patients with advanced or unresectable tumors and is an important first-line targeted drug after sorafenib. According to clinical studies, lenvatinib is equivalent to sorafenib in extending overall survival, but performs better in terms of disease control rate and progression-free survival (PFS). It can effectively inhibit liver cancer angiogenesis and tumor cell migration, and some patients can even convert from an unresectable state to a surgically resectable state after treatment.

In the treatment of differentiated thyroid cancer (DTC), lenvatinib ’s position is also stable. For patients with progressive disease who are refractory to radioactive iodine (RAI) treatment, lenvatinib can delay disease progression and improve quality of life. Overseas clinical data show that patients treated with lenvatinib have significantly longer progression-free survival, and some lesions have even shrunk. Its mechanism of action mainly blocks the angiogenesis and signal transduction pathways of thyroid cancer cells, inhibits cancer cell proliferation, and provides patients with more treatment opportunities.

In addition, in the field of endometrial cancer, the combination of lenvatinib and the immune drug pembrolizumab is considered a major breakthrough. The combination has been approved by the United StatesFDA approved for the treatment of relapsed or advanced patients who have failed platinum-based chemotherapy. The role of Lenvatinib is not only to inhibit tumor angiogenesis, but also to improve the ability of the immune system to recognize cancer cells by regulating the tumor immune microenvironment. This dual-mechanism treatment model results in improved patient survival and disease control.

Overall, the clinical status of lenvatinib has gradually consolidated in various cancers. Whether used as monotherapy or in combination with immune drugs, it demonstrates the broad-spectrum advantage of multi-target inhibition. The success of lenvatinib not only represents the maturity of targeted therapy technology, but also reflects the direction of medicine—to achieve personalized treatment and long-term disease control through in-depth understanding of tumor molecular characteristics.

Reference materials:https://www.lenvima.com/